We’ve all heard the joke at some point — women take longer in the bathroom because they “pee more.” But is there any truth behind this bathroom stereotype? As it turns out, science is more complex than that, and the answer lies deep within the structure of our kidneys.

Biologically speaking, men generally have larger kidneys than women. But does that mean they produce more urine? Not necessarily.

A recent review of autopsy data has revealed some interesting findings. While men do tend to have physically larger kidneys, researchers aren’t entirely sure if this difference holds up once body size — such as height, weight, or body surface area (BSA) — is taken into account. In other words, just because a man has a bigger kidney doesn’t automatically mean it's more efficient or produces more urine.

Size Doesn’t Always Equal Output

However, here's where it gets interesting: When kidney size is adjusted relative to body size, men may not actually have significantly larger kidneys than women. And in clinical settings, women often show better kidney health outcomes over time. Studies suggest that women are less likely to develop or progress to chronic kidney disease (CKD), even though they may report more frequent urination.

So Why Do Women Feel the Urge More Often?

Hormonal fluctuations during menstruation, pregnancy, or menopause also play a significant role in urinary patterns. Estrogen, for instance, affects the urinary tract and can make women more sensitive to the urge to go.

What It All Means

Ultimately, urination is a deeply personal — and variable — experience. If you find yourself making more frequent bathroom visits than usual, regardless of gender, it might be worth discussing with a healthcare provider.

Because when it comes to your health, every drop matters.

Parkinson’s disease (PD) symptoms differ between women and men, a new study has found, with potential implications for treatment.

Presented at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, the study found that women experienced more severe motor complications and depression. Men, however, had greater cognitive impairment.

“Sex differences in movement disorders remain understudied and undervalued despite having an important impact on clinical outcomes in both real-life and clinical trial settings,” said Dr. Marina Picillo, assistant professor of neurology at AOU San Giovanni di Dio e Ruggi d’Aragona.

What Did The Study Find?

Researchers retrospectively analyzed 10 years of clinical data from more than 10,000 Parkinson’s patients examined at a movement disorders clinic in Germany.

The findings showed that women had a greater burden of motor complications and depression. Men were more likely to experience cognitive impairment, REM sleep behavior disorder (RBD) and loss of smell.

“By analyzing data for more than 10,000 PD patients, this study confirmed that depression is more common in women, while RBD, worse cognition, and poorer olfaction are more prevalent in men,” Picillo said. “With good representation of women (40%), it also confirmed a greater female burden of motor complications.”

How Could The Findings Help?

The findings highlight the need to account for sex differences in Parkinson’s disease management and clinical trial design, particularly given the historical underrepresentation of women in neurological research. However, the factors underlying these differences remain unclear.

Picillo stressed that considering sex differences when tailoring treatment and designing clinical trials could be an important first step toward precision medicine in Parkinson’s disease.

“This would be the very first, basic step for boosting precision medicine in PD,” she said.

What Is Parkinson’s Disease?

Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing nerve cells in the brain.

Common symptoms include tremors, muscle stiffness, slowed movement and impaired balance. As the disease progresses, patients may have difficulty walking, speaking and performing everyday tasks.

The condition can also cause cognitive impairment, depression, anxiety, sleep disturbances, pain and swallowing difficulties, affecting patients’ independence and quality of life. Although it primarily affects older adults, younger people can also develop Parkinson’s disease.

Global Burden Of Parkinson’s Disease

Parkinson’s disease affected an estimated 11.9 million people worldwide in 2021. The number is projected to reach 25.2 million by 2050, a 112% increase.

Can Parkinson’s Disease Be Prevented?

There is currently no established way to prevent Parkinson’s disease. However, research suggests that certain lifestyle and environmental factors may influence disease risk.

• Physical activity: Regular exercise supports overall health, although its role in preventing Parkinson’s disease remains under investigation.
• Diet and nutrition: A balanced diet supports brain health, but no specific diet has been proven to prevent the disease.
• Environmental factors: Exposure to certain pesticides and other environmental pollutants has been associated with Parkinson’s disease risk. Reducing harmful exposures may help address potential risk factors.

Auto antibodies that target the body’s DNA-repair process may provide researchers with some clues about why some children develop cancer. It has opened new avenues for early detection and appropriate treatment, according to a study published in Frontiers in Immunology recently.

A team of researchers from Norway, through the study, identified that children with cancer were more likely to have antibodies that target proteins tasked with repairing damaged DNA.

In a separate group of children whose blood samples had been collected years before they developed cancer, those who were later diagnosed were about eight times more likely to carry these antibodies than their peers who remained free of cancer.

The findings suggest that these antibodies could be an important marker of early indicator of cancer risk. However, the researchers state that further studies are needed to prove whether the antibodies contribute to cancer development and whether they can reliably predict the disease years before.

How Antibodies Interfere With DNA Repair?

Also read: Pope Leo XIV’s Lung Cancer Diagnosis: When Should You Worry About Lung Nodules?

Antibodies are proteins that are generated by the immune system. They help recognise and neutralise foreign bodies, like viruses and bacteria.

Sometimes, however, the immune system produces autoantibodies, which mistakenly target the body’s own proteins.

The study found that some children with cancer had elevated levels of autoantibodies against six proteins involved in DNA repair. They are RAD52, NUMA1, ALKBH7, APBB1, UNG and MGMT.

DNA repair is essential because cells constantly go through damage that can lead to errors into their genetic material. When these errors are not corrected, mutations may accumulate and gradually contribute to cancer.

The researchers proposed an unproven theory that the antibodies might enter cells and bind to protein responsible for DNA repair, interfering with their normal function.

Their laboratory experiments provided evidence that these antibodies can enter living cells and localise to a cellular compartment called the TIGER domain.

“We showed that many children with various types of cancer have antibodies against some of their own DNA repair proteins. We also demonstrated that such ‘auto-antibodies’ can enter live cells and bind to – and probably inhibit – the activity of these essential proteins,” said corresponding author Dr Ola Myklebost, emeritus professor of molecular oncology at the University of Bergen.

If the antibodies do impair DNA repair, they could contribute to the accumulation of genetic damage. However, this mechanism has not yet been conclusively observed in humans.

Could A Blood Test Predict Cancer Years In Advance?

Also read: Landmark Study Links Air Pollution To Higher Hospital Admissions For Cancers & Mental Health Disorders: Lancet

To investigate whether the antibodies appeared before cancer diagnosis, the researchers examined blood samples from 59 children who participated in two British long-term studies: the Avon Longitudinal Study of Parents and Children and Born in Bradford.

Half of the children were subsequently diagnosed with cancer before the age of 30, while the other half had not developed the disease. On average, the blood samples from those who later developed cancer had been collected approximately six years before diagnosis.

“Although this cohort is small, it was the best we could find internationally,” Myklebost said.

He added that children who later developed cancer were about eight times more likely to have antibodies against at least one key DNA-repair protein.

The researchers analysed samples from a broader group of 375 healthy individuals and patients, alongside cancer samples from adults and children with sarcoma or acute lymphoblastic leukaemia.

Childhood cancers are often biologically different from adult cancers. Unlike many adult malignancies, which can accumulate mutations over decades, paediatric cancers may arise in developing cells with fewer accumulated genetic changes. The researchers believe the immune system could play an important role in some cases.

However, the findings do not establish that the antibodies cause cancer. The study also cannot determine how accurately an antibody test would predict future disease in the general population.

The researchers are now investigating whether these antibodies affect DNA repair in laboratory-grown cells and plan to study their potential cancer-causing effects in animal models.

“At present we are investigating the effect of patient antibodies on the repair of induced mutations in cultured cells. Ultimately, we hope to clone white blood cells that secrete such auto-antibodies, and test for any cancer causing effects in mice to definitively prove our hypothesis,” Myklebost said.

Atorvastatin, a widely prescribed statin, helps lower cholesterol and reduce the risk of heart attacks and strokes. However, stopping the medication without medical advice can allow cholesterol levels to rise

again. Higher cholesterol levels have been linked to increased risk of heart attacks and other cardiovascular conditions.

Pharmacist Raj Patel recently warned about this in a TikTok video, comparing stopping the drug to giving up regular exercise.

“What happens if you stop taking atorvastatin? You know when you stop exercising for a month and everything slips back?” Patel asked.

“That's what happens when you stop atorvastatin. Your cholesterol creeps back up and so does your heart attack risk,” he warned.

According to the UK's National Health Service (NHS), cholesterol levels may rise again after stopping atorvastatin. Patients should continue taking it unless their doctor advises otherwise.

What Is Atorvastatin?

Also read: Confused By Your Cholesterol Report? Here's What LDL And ApoB Really Mean

Atorvastatin belongs to a class of medicines called statins. It reduces cholesterol production in the liver and helps prevent heart attacks and strokes. Doctors may prescribe it to people with high cholesterol or an increased risk of cardiovascular disease, including those with diabetes or a family history of heart disease.

High cholesterol can cause fatty deposits to build up inside blood vessels, restricting blood flow. Statins help lower cardiovascular risk, particularly in people with existing heart disease or other risk factors.

Which Medicines Interact With Atorvastatin?

The NHS previously warned that certain medicines can interact with atorvastatin and increase the risk of serious side effects, including muscle damage. Patients should tell their doctor or pharmacist about all medicines and supplements they take.

On its website, the NHS lists certain “cautions with other medicines.” This means you should check that atorvastatin is safe to take alongside any other drugs or supplements.

Read More: You Feel Healthy. But Plaque May Already Be Building In Your Arteries In Your 20s

The NHS explained: “Some medicines can affect the way atorvastatin works and can increase the chances of you having serious side effects, such as muscle damage.” You should tell your doctor or pharmacist if you are taking any of the following:

• Antibiotics: Erythromycin, clarithromycin, rifampicin and fusidic acid
• Antifungals: Ketoconazole, voriconazole and fluconazole
• Other treatments: Certain HIV and hepatitis C medicines
• Other medicines: Warfarin, ciclosporin, colchicine and some contraceptive pills
• Heart medicines: Verapamil, diltiazem, amlodipine and amiodarone

Depending on the interaction, a doctor may adjust the dose, prescribe another statin or temporarily pause treatment. Check with a healthcare professional before taking supplements.

What Are The Common Side Effects?

According to the NHS, common side effects affecting more than one in 100 people include:

• Nausea or indigestion
• Headaches and nosebleeds
• Sore throat and cold-like symptoms
• Constipation, bloating or diarrhea

“Drinking large amounts of alcohol regularly increases the risk of side effects and liver problems while taking atorvastatin,” the NHS added. “If side effects make you want to stop taking the medicine, speak to your doctor first. They may be due to another cause, and your doctor can suggest lowering the dose or switching medicines.”